The Neffy could pave the way for Canada's future in allergy care
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “The Neffy could pave the way for Canada's future in allergy care” inside PodZeus.
This episode of The Big Story explores the recent approval of NEFI, a nasal spray version of epinephrine, by Health Canada—a breakthrough that could transform allergy care in Canada. Host Maria Kastane speaks with Dr. Mariam Hanna, a pediatric allergist and clinical immunologist, about the rising prevalence of anaphylaxis across all age groups, particularly the growing number of adults developing new-onset food, medication, and venom allergies. The discussion highlights the limitations of current treatment options, the psychological and logistical barriers to using EpiPens, and the importance of shifting from a 'diagnose and adios' model to lifelong patient empowerment. Dr. Hanna emphasizes the need for better transition support from pediatric to adult care, self-advocacy, and updated guidelines. The NEFI nasal spray offers a needle-free, fast-acting alternative that’s already in use in the U.S., with potential to increase access and reduce fear around emergency treatment. The episode also touches on emerging therapies like oral, sublingual, and epicutaneous immunotherapies, as well as the role of biologics in blocking allergic reactions. Despite progress, challenges remain around cost, access, and national policy coordination, with advocates pushing for a unified national anaphylaxis action plan. Key takeaways include: 1) The NEFI nasal spray is a game-changing, needle-free epinephrine option that could improve emergency response rates; 2) Adults with allergies often fall through the cracks after transitioning from pediatric care—self-advocacy and ongoing medical follow-up are critical; 3) New treatments like immunotherapies and biologics are expanding options beyond avoidance and epinephrine; 4) Public awareness and policy changes are needed to ensure epinephrine is available in workplaces, schools, and public spaces; 5) The approval of NEFI reflects a broader shift toward patient-centered, accessible allergy care. The episode ends with a call to action for listeners to share their experiences and help drive systemic change.
NEFI, a nasal epinephrine spray, offers a needle-free, equally effective alternative to EpiPens and could significantly improve emergency response rates.
Adults with allergies often lack support after transitioning from pediatric care—self-advocacy and regular reassessment with allergists are essential.
Emerging treatments like oral, sublingual, and epicutaneous immunotherapies are expanding options beyond avoidance and epinephrine.
Public policy and national guidelines are needed to ensure epinephrine is accessible in workplaces, schools, and public spaces.
The approval of NEFI marks a shift toward more accessible, user-friendly allergy care, but cost and access remain key challenges.
The Rise of Anaphylaxis in Canada
The episode opens with a discussion on the growing prevalence of anaphylaxis in Canada, particularly among children and adults, and the urgent need for better access to emergency treatment.
Understanding Anaphylaxis: Triggers and Symptoms
Dr. Hanna explains what anaphylaxis is, its varied symptoms, and the three main triggers: food, medications, and venom, emphasizing how the immune system overreacts to harmless substances.
The Global and Canadian Allergy Epidemic
The episode examines rising allergy rates in industrialized nations, particularly Canada, and explores environmental and lifestyle factors like microbiome changes and vitamin D exposure that may contribute to this trend.
From Diagnosis to Lifelong Management
“You're not just diagnosed and adios. You're managing this every single day, and you need to be empowered to advocate for yourself.”
The Future of Allergy Treatment: Beyond Epinephrine
“We're not just treating symptoms anymore—we're training the immune system and blocking the reaction before it starts.”
“We're not just treating symptoms anymore—we're training the immune system and blocking the reaction before it starts.”
“The NEFI is needle-free, fast-acting, and could revolutionize how we respond to anaphylaxis—especially in settings where fear of needles has been a barrier.”
“You're not just diagnosed and adios. You're managing this every single day, and you need to be empowered to advocate for yourself.”
Host
Guest
Dr. Mariam Hanna
person
NEFI
product
Maria Kastane
person
Health Canada
organization
EpiPen
product
oral immunotherapy
other
sublingual immunotherapy
other
epicutaneous immunotherapy
other
biologics
other
National Anaphylaxis Action Plan
other
Has Ontario lost its way with colleges?
The Big Story • 24m • 3/31/2026
Canada is torn over the notwithstanding clause
The Big Story • 26m • 4/1/2026
Does Canada need to rethink its Emergencies Act?
The Big Story • 26m • 4/2/2026
What is functional health and why is it declining for Canadians?
The Big Story • 25m • 4/3/2026
Weekend Listen: Q1 Recap: Market swings, mayhem and Trump
The Big Story • 19m • 4/4/2026
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “The Neffy could pave the way for Canada's future in allergy care” inside PodZeus.
Start discovering podcast insights today
Start with a 7-day trial and explore a growing catalog of popular podcasts. No credit card required.
No credit card required • 7-day trial • Cancel anytime
